ROPIVACAINE

Ovarian Cyst

San Gerardo HospitalSmall moleculePhase 3Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

2 Active assets in the Ovarian Cyst cohort.

Asset / Sponsor	Phase	Rating
Danazol Centre for Endocrinology and Reproductive Medicine, Italy	Phase 4	BB
Letrozole Wake Forest University Health Sciences	Phase 4	BB
Cetrotide Zagazig University	Phase 4	BB
Ganirelix Assaf-Harofeh Medical Center	Phase 4	BB
Adhexil OMRIX Biopharmaceuticals	Phase 3	B

View all 13 →

Same molecule, other indications

ROPIVACAINE is also rated in:

osteoarthritis, hipActive

BBB

Indicative · Phase 4

76 / 100

post-operative pain, non-human animalActive

BBB

Indicative · Phase 4

76 / 100

cerebral palsyActive

BB

Indicative · Phase 4

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.